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Background: MED12 and TERT promoter mutations have been shown to be the most common somatic mutations in phyllodes
tumours (PTs). The aims of this study were to determine the frequency of these mutations in recurrent PTs, assess whether TERT
promoter mutations could be helpful in distinguishing fibroadenomas (FAs) from PTs and identify novel mutations that may be
driving malignant progression.
Methods:MED12 and the TERT promoter were Sanger sequenced in 75 primary PTs, 21 recurrences, 19 single FAs and 2 cases of
multiple FAs with benign PTs. Whole-exome sequencing was performed on one borderline PT.
Results: Recurrent PTs and multiple FAs showed temporal discordance in MED12 but not TERT. Recurrent samples did acquire
TERT mutations, with recurrent benign PTs more likely to have mutations in both genes. TERT mutations were not helpful in
differentiating between benign PTs and FAs in cases of multiple FAs/PTs. Exome sequencing revealed a nonsense mutation in
RBM15 and Sanger sequencing revealed another three RBM15 mutations in malignant/borderline PTs.
Conclusions: This study has shown that MED12 mutations can be heterogeneous in both synchronous and recurrent PTs unlike
TERT mutations. We have also shown that RBM15 mutations may be important in the pathogenesis of borderline/malignant PTs.
Phyllodes tumours (PTs) are rare fibroepithelial neoplasms of the
breast composed of both stromal and epithelial elements similar to
fibroadenomas (FAs) but with a more cellular stromal element.
Histologically, PTs are classified as benign, borderline or malignant
on the basis of stromal cellularity, nuclear atypia, mitotic activity,
stromal overgrowth and type of border (infiltrating or pushing)
(Lakhani et al, 2012). Borderline PTs have some but not all of the
features of malignant PTs. Unlike FAs, PTs can recur locally and
metastasise as sarcoma. Stromal atypia, mitoses, overgrowth and
surgical margin status have been shown to be independent
predictors of local recurrence (Tan et al, 2012). Most recurrent
benign and borderline tumours are histologically similar to the
primary neoplasms but can be more cellular, and malignant
transformation has been described (Jones et al, 2008).
Recent sequencing studies have shown that MED12 exon 2
mutations occur in approximately 70% of PTs and FAs (Cani et al,
2015; Nagasawa et al, 2015; Yoshida et al, 2015a; Lien et al, 2016a).
Some studies suggest that the frequency is similar across both FAs
and all grades of PTs (Cani et al, 2015; Yoshida et al, 2015a;
Nagasawa et al, 2015; Lien et al, 2016a) and others that they are
less frequent in malignant PTs (Pfarr et al, 2015; Piscuoglio et al,
2015) and FAs (Ng et al, 2015). This variation may be due to the
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type of FAs included in the series as two studies have shown
MED12 mutations are more common in intracanalicular than
pericanalicular FAs (Yoshida et al, 2015a, b; Mishima et al, 2015).
In both PTs and FAs, mutations are confined to the stromal
component (Yoshida et al, 2015a, b; Mishima et al, 2015). PTs with
MED12 mutations tend to have lower recurrence rates than PTs
without MED12 mutations (Ng et al, 2015; Yoon et al, 2016).
MED12 exon 2 mutation can also help distinguish PTs from other
spindle neoplasms of the breast, such as sarcomas (Lien et al,
2016b).
The finding in some studies that MED12 mutations are less
frequent in malignant PTs suggests that these tumours may be
driven by other genetic events. Exome and targeted sequencing
studies of malignant PTs have shown that they harbour recurrent
mutations in the TERT promoter, TP53, RB1, EGFR, PIK3CA,
FGFR1, SETD2 and KMT2D (Tan et al, 2015; Gatalica et al, 2016;
Liu et al, 2016), with TERT promoter mutations being the most
frequent, occurring in B70% of malignant/borderline PTs. TERT
promoter mutations are also found in benign PTs (B50%) but are
not as frequent as in malignant/borderline PTs (Yoshida et al,
2015b; Piscuoglio et al, 2016). They are rare in FAs (0–7%),
suggesting that these mutations drive the progression of PTs. It has
also been suggested that TERT mutations may be useful in
distinguishing between benign PTs and cellular FAs (Tan et al,
2015), particularly in rare cases of multiple recurrent FAs where
benign PTs have occasionally been described (Courtillot et al,
2010). TERT mutations can co-exist with MED12 mutations and
similar to MED12 mutations are restricted to the stromal
component (Yoshida et al, 2015b; Piscuoglio et al, 2016).
The aims of this study were to:
1. assess MED12 and TERT promoter mutations in a series of
recurrent PTs;
2. assess whether TERT mutations could be helpful in distinguish-
ing FAs from PTs in patients with synchronous/metachronous
multiple FAs and PTs; and
3. identify novel mutations in other genes that may be driving
malignant progression of PTs.
MATERIALS AND METHODS
Sample collection. Formalin-fixed, paraffin-embedded tissue
(FFPE) was obtained from 75 primary PTs and any ipsilateral
recurrences together with two cases of multiple FAs that had
developed benign PTs from 15 centres across the United Kingdom
with ethical approval (MREC No. 03/12/083) and informed
consent. Eleven cases had paired germline DNA extracted from
blood samples. H&E-stained slides of each case were reviewed by a
single histopathologist (AH) to confirm the diagnosis and DNA
was extracted as previously described (Jones et al, 2008). Nineteen
FAs (FFPE) and one fresh-frozen borderline PT were provided by
the KHP Cancer Biobank (NHS REC ref. 12-EE-0493).
Sanger sequencing. The promoter region of TERT was amplified
by PCR as previously described (Yoshida et al, 2015b) using the
following primers: 50-CAGCGCTGCCTGAAACTC-30 and 50-
GTCCTGCCCCTTCACCTT-30. MED12 primers, targeting exon
2, were designed with the online tool Primer3: 50-TGTTCTA-
CACGGAACCCTCCTC-30 and 50-CTGGGCAAATGCCAATGA-
GAT-30. Primers for the entire RBM15 gene followed the same
design and are listed in Supplementary Table 1. Sanger sequencing
was performed in a 3730xl DNA Analyser (ThermoFisher,
Waltham, MA, USA) according to the manufacturer’s protocol.
The analysis of the electropherograms was performed in the openly
available 4peaks software.
Exome sequencing. A library was prepared from tumour and
paired constitutional DNA using the SureSelect Human All Exon
50Mb kit (Agilent, Santa Clara, CA, USA) and sequenced on
Illumina HiSeq 2000 (San Diego, CA, USA) to a mean depth of
4100 . Subsequent analysis was performed using our in-house
pipeline; in brief, sequencing reads were aligned to the reference
human genome hg19 using NovoAlign (http://www.novocraft.-
com/products/novoalign/), Samtools (http://www.samtools.source-
forge.net/) was used to create a pileup file and VarScan2 (http://
www.varscan.sourceforge.net/) was used to call somatic mutations
and indels that were annotated using ANNOVAR (http://
annovar.openbioinformatics.org/en/latest/) and cross referenced
with dbSNP and 1000 Genomes. Somatic mutations were called if
there was a minimum of 30 coverage and the mutation was
present in at least 10% of reads.
RESULTS
Seventy-five primary PTs (27 malignant, 22 borderline, 26 benign)
were studied, of which 21 had recurred at least once (Table 1,
Supplementary Table 2). Of the 21 recurrent cases, nine were
benign (one of which recurred as a borderline PT), five were
borderline (three of which recurred as malignant PTs) and seven
were malignant. Nineteen FAs were also analysed.
Frequency of MED12 mutations. MED12 mutations occurred in
22, 27, 54 and 21% of malignant, borderline and benign PTs and
FAs, respectively (Table 2). MED12 mutations were more common
in benign PTs compared with malignant/borderline (P¼ 0.02,
Fisher’s Exact Test).
MED12 mutations in recurrent PTs. Although MED12 muta-
tions appeared less common in PTs that recurred (19%) compared
with those that did not (41%); this difference was not statistically
significant (P¼ 0.1, Fisher’s Exact Test; Table 2).
In the four primary tumours with MED12 mutations that did
recur, two had the same MED12 mutation in the paired recurrent
tumour (one had two MED12 mutations and both were seen in the
recurrent sample), but in the other two cases (one malignant, one
benign), there was no evidence of the original MED12 mutation in
the recurrence.
There was also evidence of recurrent tumours acquiring MED12
mutations. Four cases (three benign, one borderline) with no
evidence of aMED12 mutation in the primary PT did haveMED12
mutations in the recurrent tumours (Table 1). Similarly, in three
cases that developed a second recurrence, none had a MED12
mutation in the primary, two had a MED12 mutation in the first
recurrence, and of these, one had the sameMED12 mutation in the
second recurrence and the other a different MED12 mutation.
Multiple MED12 mutations in the same lesion. We also found
evidence of multiple MED12 mutations in the same lesions
(Supplementary Table 3). Five primary PTs (one of which recurred
and both mutations were found in the recurrence) and another two
recurrences had multiple (2–4) MED12 mutations. Of these two
recurrences, one had no evidence of MED12 mutations in the
primary and the other had a single MED12 mutations in the
primary lesion and then acquired another three mutations in the
recurrence. All cases with multiple MED12 mutations were benign.
Frequency of TERT promoter mutations. TERT promoter
mutations occurred in 48, 55, 31 and 0% of malignant, borderline,
and benign PTs and FAs, respectively (Table 2). There was no
significant difference in the frequency of TERT mutations between
the different subtypes of PT, but as expected a clear difference
between PTs and FAs (P¼ 0.0001, Fisher’s Exact Test).
BRITISH JOURNAL OF CANCER MED12, TERT promoter, RBM15 mutations in phyllodes tumours
278 www.bjcancer.com |DOI:10.1038/bjc.2017.450
TERT promoter mutations in recurrent PTs. Similar to MED12,
there was no evidence that TERT promoter mutations were
more or less common in cases that recurred (28% recurrent vs 50%
non-recurrent). However unlike MED12 all seven of the primary
PTs with a TERT promoter mutation that recurred showed
evidence of the mutation in the paired recurrence. Of those, three
(benign) had a second recurrence, which also had evidence of the
mutation.
There was also evidence of recurrent tumours acquiring TERT
promoter mutations with four (one malignant, one borderline and two
benign) acquiring a TERT promoter mutation in the first recurrence
and again this was also found in subsequent recurrences (Table 1).
Table 1. Detailed table of recurrences and their MED12 and TERT promoter mutations
Sample
ID
Gene
Primary
subtype
Primary mutation
Recurrence 1
subtype
Recurrence 1 mutation
Recurrence 2
subtype
Recurrence 2
mutation
1 MED12 M No M No
TERT M c.-124C4T M c.-124C4T
2 MED12 M No M No
TERT M No M No
3 MED12 M No M No M No
TERT M No M c.-124C4T M c.-124C4T
4 MED12 M c.131G4A M No
TERT M No M No
5 MED12 M No M No
TERT M No M No
6 MED12 M No M No
TERT M No M No
7 MED12 M No M No
TERT M No M No
8 MED12 Bo No M No
TERT Bo c.-124C4T M c.-124C4T
9 MED12 Bo No M c.100-13T4C
TERT Bo No M No
10 MED12 Bo No M No
TERT Bo No M c.-124C4T
11 MED12 Bo No Bo No
TERT Bo No Bo No
12 MED12 Bo No Bo No
TERT Bo No Bo No
13 MED12 B No B c.138_164del27 B Fail
TERT B c.-124C4T B c.-124C4T B Fail
14 MED12 B No B No
TERT B No B No
15 MED12 B c.123_152del30 and
c.119A4T
B c.123_152del30 and c.119A4T
TERT B No B c.-124C4T
16 MED12 B No Bo No
TERT B No Bo No
17 MED12 B c.131G4C B c.128A4C, 129A4G, c.131G4C,
c.133_152del30
TERT B c.-124C4T B c.-124C4T
18 MED12 B No B c.120_146del27 B c.113_151del39
TERT B c.-124C4T B c.-124C4T B c.-124C4T
19 MED12 B No B c.122_148_del27 B c.122_148_del27
TERT B c.-124C4T B c.-124C4T B c.-124C4T
20 MED12 B c.124_156del33 B No
TERT B No B No
21 MED12 B No B c.148G4A and c.133_147del15
TERT B No B c.-124C4T
Abbreviations: B¼benign; Bo¼borderline; M¼malignant.
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Analysis of two cases of multiple FAs and PTs. In order to assess
whether TERT promoter mutations could be useful in distinguish-
ing between benign PTs and FAs in patients with multiple FAs, we
analysed cases from two young women who developed bilateral
multiple recurrent FAs and subsequently developed benign PTs
(Supplementary Figure 1). The first, aged 22 years, developed
multiple bilateral FAs over a period of 3 years and was diagnosed
with benign PTs on the fourth recurrence. Nine lesions (7 FAs and
2 PTs) were examined from the 4-year period and none showed
any evidence of TERT mutations. At the fourth recurrence, MED12
mutations were identified in one cellular FA (c.130G4A) and one
benign PT (c.130G4A and c.136_150del15). The second case
occurred in a 20-year-old with bilateral multiple FAs that started to
increase in size and so were excised and found to be a cellular FA
and two benign PTs. Sequencing of each lesion showed no TERT
mutations and a different MED12 mutation in each of the lesions
(c.107T4G, c.131G4A and c.100-8T4A).
Novel drivers of malignant and borderline PTs. In an attempt to
identify other drivers of malignant and borderline PTs, we
performed whole-exome sequencing of a single borderline case
who had DNA available from fresh-frozen tumour and blood.
Eighteen somatic mutations were identified but no MED12
mutation (Table 3). The mutations were ranked according to the
variant allele frequency within the tumour, on the assumption that
those with a frequency of B50% were less likely to be subclonal
and more likely to be driver mutations. Five mutations with a
variant frequency of 40–64% were identified and verified by Sanger
sequencing in DNA extracted from FFPE material from the same
tumour. Only one of these genes, RBM15, had previously been
identified as harbouring a mutation in a PT (Tan et al, 2015;
borderline PT with a frameshift RBM15 mutation, c.598_601delG-
TAA). We therefore chose to Sanger sequence this gene in another
27 malignant, 17 borderline (including one recurrent sample) and
16 benign (including five recurrent samples) and found another
three different mutations, two in malignant PTs and one in a
borderline PT (Table 4, Figure 1, Supplementary Figure 2).
DISCUSSION
MED12 and TERT promoter mutations have previously been
shown to be the most common mutations in PTs. This study,
similar to others (Table 5A), has shown that MED12 mutations are
more common in benign PTs than malignant and borderline PTs
Table 2. Frequency of MED12 and TERT promoter mutations in recurrent and non-recurrent phyllodes tumours and
fibroadenomas
Malignant PTs Borderline PTs Benign PTs Fibroadenomas
Mutation
All
cases
(n¼27)
Cases that
did not
recur
(n¼20)
Cases
that did
recur
(n¼7)
All
(n¼22)
Cases that
did not
recur
(n¼17)
Cases
that did
recur
(n¼5)
All
(n¼26)
Cases that
did not
recur
(n¼17)
Cases
that did
recur
(n¼9)
(n¼19)
MED12
exon 2
mutations
6 (22%) 5 1 6 (27%) 6 0 14 (54%) 11 3 4 (21%)
TERT
promoter
mutations
13 (48%) 12 1 12 (55%) 11 1 8 (31%) 4 4 0
Abbreviation: PT¼phyllodes tumour.
Table 3. Somatic mutations identified by whole exome sequencing of a single borderline phyllodes tumour
Chrom Gene Site of mutation Annotation % of reads with mutation
chr1 RBM15 Exonic RBM15:NM_001201545:exon1:c.A583T:p.K195X: stopgain 64.20%
chr1 VASH2 Splicing VASH2:NM_024749:exon4:c.366-1G4C 61.54%
chr11 ROBO3 Splicing ROBO3:NM_022370:exon12:c.1785-4G4T 44.44%
chr11 TRIM49C Exonic TRIM49C:NM_001195234:exon3:c.T185C:p.I62T 41.63%
chr3 CAND2 Exonic CAND2:NM_001162499:exon10:c.A2030G:p.D677G 40.23%
chr15 PLA2G4F Exonic PLA2G4F:NM_213600:exon1:c.27delG: frameshift deletion 37.88%
chr2 NEB Exonic NEB:NM_001164507:exon37:c.G4182T:p.K1394N 35.97%
chr10 ENKUR Exonic ENKUR:NM_145010:exon2:c.T198A:p.H66Q, 35.26%
chr1 YIPF1 Exonic YIPF1:NM_018982:exon4:c.T89C:p.I30T, 34.45%
chr5 PCDHA11 Exonic PCDHA11:NM_031861:exon1:c.C1446A:p.D482E 32.03%
chrX FAM58A Exonic Unknown 21.86%
chr12 LIMA1 Splicing LIMA1:NM_016357:exon9:c.973-3G4- 20.83%
chr1 CACNA1S Splicing CACNA1S:NM_000069:exon5:c.399-6T4C 17.43%
chr15 ZNF280D Splicing ZNF280D:NM_017661:exon11:c.781-8C4- 16.28%
chr14 RALGAPA1 Splicing RALGAPA1:NM_014990:exon11:c.1012-8G4-, 15.58%
chr19 SSC5D Exonic SSC5D:NM_001144950:exon14:c.T4361C:p.L1454P 15.38%
chr11 BRSK2 Exonic BRSK2:NM_001256630:exon1:c.A17C:p.H6P, 15.15%
chr20 BCAS4 Exonic BCAS4:NM_198799:exon2:c.T191G:p.V64G 15%
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and TERT promoter mutations are rare in FAs. By analysing paired
primaries and recurrences, we have been able to assess whether
these mutations are also present in paired recurrences or whether
there is evidence of temporal heterogeneity. We have demonstrated
that MED12 is frequently heterogeneous between lesions from the
same patient, in contrast to TERT promoter mutation that are
consistently found in paired recurrences, including those with
multiple recurrences. Lae et al (2016) also demonstrated temporal
heterogeneity within MED12 (they did not assess TERT). In their
study, the heterogeneous recurrences had different MED12
mutations from the primary case, this occurred in one of our
recurrent cases (a second benign recurrence) but the remainder
(one benign, one malignant) lacked a MED12 mutation in the
paired recurrent sample, suggesting that they were either new
primaries or had arisen from a subclone within the primary PT
that did not contain the MED12 mutation. Unlike Lae et al (2016),
we also have evidence of four cases of wild-type MED12 primaries
acquiringMED12 mutations in the second event (three benign, one
borderline) and of benign PTs harbouring multiple (2–4) MED12
mutations in the same lesion. As Sanger sequencing will only detect
clonal mutations, we cannot exclude the possibility that it was a
subclonal mutation in the primary tumour which we cannot detect.
These findings suggest thatMED12 are not only just early events in
fibroepithelial tumours but also provide some growth advantage in
established benign PTs.
A number of recurrences also acquired TERT promoter muta-
tions, (4 cases – 2 benign and 2 malignant). In the series of PTs
described by Yoshida et al 2015b; TERT andMED12 mutations were
frequently found together (Table 5B). We did not see this in the
primary cases, 41% of PTs with TERT promoter mutations
harboured MED12 mutations, which is similar to (Piscuoglio et al,
2016) (52%) and (Liu et al, 2016) (50%). However, in the recurrent
samples TERT and MED12 mutations frequently co-occured
(P¼ 0.05, Fisher’s Exact test), particularly in benign cases where
acquisition of MED12 and TERT promoter mutations resulted in six
out of nine benign recurrences having both a TERT and MED12
mutation compared with one out of nine of their paired primary
samples. In contrast, none of the malignant/borderline recurrences
had mutations in both genes. This suggests that although they can
co-exist TERT promoter mutations are not dependent on MED12
mutations. As postulated by (Piscuoglio et al, 2016) TERT promoter
mutations may allow the stroma of PTs to undergo more cycles of
cell division and thus increase the chance of them acquiring a driver
mutation.
The lack of TERT promoter mutations in FAs has led some
authors to suggest that this mutation may be useful for
distinguishing between FAs and benign PTs in rare cases of
multiple FAs and benign PTs. In two such cases, we found no
evidence of TERT promoter mutations in either the FAs or benign
PTs. The analysis of these multiple tumour cases once again
demonstrated heterogeneity ofMED12. In the first case, noMED12
mutation was present in the initial FAs and only appeared at the
time of the fourth recurrence when a cellular FA and benign PT
were diagnosed on histology – the presence of the same mutation
suggested a common clonal origin, although the PT had also
acquired a secondMED12 mutation. In contrast, in the second case
(a cellular FA and two benign PTs), all three lesions had different
MED12 mutations, suggesting that they arose independently
(Supplementary Figure 1).
The mechanism through which MED12 mutations confer a
growth advantage to FAs and benign PTs is not clear. MED12
mutations are also frequent in uterine leiomyomas but less so in
uterine leiomyosarcomas (Ravegnini et al, 2013). A possible
explanation for this is that MED12 mutations drive benign
proliferation of smooth muscle and stroma in the uterus and
breast, respectively, resulting in leiomyomas and FAs/benign PTs.
In rare cases, these benign lesions progress to leiomyosarcoma and
malignant PTs, but the majority of these malignant tumours arise
de novo and therefore do not have MED12 mutations.
The exome sequencing of the single borderline PT with fresh-
frozen tissue did not reveal any MED12 mutation and no TERT
promoter mutation was found on Sanger Sequencing, but it did
identify mutations in 18 genes, none of which had been previously
identified as driver mutations in any type of cancer. The most
frequent variant in this PT was a nonsense mutation in RBM15,
an RNA-binding protein on 1p13.3 involved in regulating
splicing of GATA1 and RUNX transcription factors in megakar-
yocyte differentiation and translocated in infant acute megakar-
yocytic leukaemia (Tran et al, 2016). Interestingly, previously
published array CGH data of this tumour (Jones et al, 2008)
showed loss in this region (1:105666811-117575143, GRCh37/
hg19), Supplementary Figure 3.
A frameshift mutation (c.598_601delGTAA) in RBM15 was also
detected by exome sequencing by (Tan et al, 2015) in a borderline
PT but was not remarked upon as a possible driver gene. All other
PT sequencing studies have used targeted sequencing panels that
have not included RBM15. Sanger sequencing of our tumour series
identified a further three RBM15 mutations in malignant/border-
line PTs, two of which were nonsense or frameshift changes and
one of which was a missense mutation, not predicted to be
deleterious but located at the start of a highly conserved C-terminal
SPOC (Spen paralog and ortholog C-terminal) domain. One
hundred and sixty-six mutations in RBM15 have been catalogued
in COSMIC (http://cancer.sanger.ac.uk/cosmic), of which only 10
are nonsense and occur in a variety of solid tumours, including
bladder, head and neck, colorectal, stomach, prostate and pancreas.
As well as being involved in the development of megakaryocytic
leukaemia, RBM15 is an important factor in X chromosome
silencing (Moindrot et al, 2015) and has been shown to be
expressed in mammary tissue (https://www.gtexportal.org/home/).
It is therefore not unreasonable to suggest that a truncated or
absent RBM15 protein may confer a growth advantage in PTs.
Of the five RBM15 mutations that have now been described
in PTs (four in this study, one by Tan et al, 2015), three occurred
in malignant/borderline PTs that did not harbour MED12 or
TERT promoter mutations. Previous literature also suggests that
PIK3CA mutations are more common in PTs that do not harbour
MED12 mutations (Tan et al, 2015; Piscuoglio et al, 2016). In
Table 4. RBM15 mutations
Sample ID Histopath subtype Mutation DNA Mutation AA DANNa score CADDb score
22 Borderline c.583A4T p.195K4a 0.999 26.3
23 Malignant c.1924C4T p.642R4a 0.995 36
24 Borderline c.715delG p.239V4fsa1 NA (del) NA (del)
25 Malignant c.2344C4T p.782P4S 0.886 11.13
Abbreviations: NA¼not applicable.
aDANN (https://doi.org/10.1093/bioinformatics/btu703) uses a 0–1, scale. Score X0.96 identifies 92% of the true positive pathogenic variations, with 18.1% false positive benign variations.
bCADD (cadd.gs.washington.edu/). A scaled CADD score of 20 means that a variant is among the top 1% of deleterious variants in the human genome. Scaled CADD score of 30 means that the
variant is in the top 0.1%.
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contrast, RARA mutations were more frequent in samples with
MED12 and TERT promoter mutations (Tan et al, 2015; Piscuoglio
et al, 2016) and thus may provide a selective advantage when
TERT/MED12 are mutated.
In conclusion, we have shown that, although MED12 mutations
are common in both benign PTs and FAs, suggesting that they are
sometimes early events in fibroepithelial lesions of the breast, they
can be discordant in recurrent PTs, particularly in benign cases
where they can be lost or acquired with some cases carrying
multiple mutations inMED12. There was less evidence of temporal
heterogeneity in TERT promoter mutations, but recurrent samples
did acquire TERT promoter mutations, supporting previous data
from our laboratory that recurrent samples often acquired new
genetic changes (Jones et al, 2008).
Through exome sequencing of a single malignant PT, we have
shown that RBM15 may be a novel driver mutation in malignant/
0
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10 20 30 40
210200190180
190 200 210
Figure 1. RBM15 mutations identified by Sanger sequencing. (A) Sample 23 (c.1924 C4T, p.R642*). (B) Sample 24 (c.715delG, p.V239fs*1) –
correct sequence shown above, shifted sequence shown below (reverse sequence shown in Supplementary Figure 2). (C) Sample 25 (c.2344C4T,
p.P782S).
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Table 5A. Summary of previous published data on MED12 mutations in FAs and PTs
Publication
Number
of PTs in
the study
Frequency
in FAs
Frequency
in benign
PTs
Frequency
in Bo PTs
Frequency
in
malignant
PTs
Frequency
in PTs that
recurred vs
none
recurrent
cases
Evidence of
temporal
heterogeneity
in recurrent
PTs
Evidence
of
acquisition
of
mutations
in
recurrent
PTs
Evidence of
heterogeneity
in
synchronous
PTs/FAs
Lae et al
(2016)
83 primary
14
recurrences
70% 58.3% 63.3% 27.6% 50% vs 49% Yes 3/6
recurrences had
different MED12
mutations
compared with
primary tumour
No NA
Cani et al
(2015)
15 NA 80% 80% 40% NA NA NA NA
Lien et al
(2016a)
49 47.1% 72.7% 70.6% 70% NA NA NA NA
Liu et al
(2016)
30 NA NA NA 30% NA NA NA NA
Mishima et al
(2015)
24 primary
2
recurrences
47% 80% 67% 0% 50% vs 82% No No Yes: 6 cases
Nagasawa
et al (2015)
11 67% NA NA NA NA NA NA NA
Ng et al
(2015)
112 primary
10
recurrences
59% 65.1% 65.6% 42.8% Higher
recurrence
likelihood in
those without
MED12
mutations
NA NA NA
Pfarr et al
(2015)
16 62% 73% NA 20% NA NA NA NA
Piscuoglio
et al (2015)
47 65% 88% 78% 8% NA NA NA Yes: 4 cases
Piscuoglio
et al (2016)
76 NA 80% 64% 23% NA NA NA NA
Tan et al
(2015)
79 86% 82% 63% 60% NA NA NA No: 1 case
Yoon et al
(2016)
176 number
of
recurrences
not stated
71.4% 51% 26.9% MED12
mutations
associated
with a non-
significant
improvement
in DFS
NA NA NA
Yoshida M
et al (2015)
46 62% 83% 80% 77% NA NA NA NA
Current
study
75 primary
21
recurrences
21% 54% 27% 22% 19 vs 41% Yes Yes Yes
Abbreviations: DFS¼disease-free survival; FA¼ fibroadenoma; NA¼ not assessed; PT¼phyllodes tumour.
Table 5B. Summary of previous published data on TERT promoter mutations in FAs and PTs
Publication
Number
of PTs in
the study
Frequency
in FAs
Frequency
in benign
PTs
Frequency
in Bo PTs
Frequency
in
malignant
PTs
Frequency in PTs
that recurred vs
none recurrent
cases
Evidence of
acquisition of
mutations in
recurrent PTs
Evidence of
heterogeneity
in synchronous
PTs/FAs
Liu et al
(2016)
30 NA 0% 33% 60% NA NA NA
Piscuoglio
et al (2016)
76 NA 18% 57% 68% NA NA NA
Yoshida et al
(2015a,b)
46 7% 50% 87% 62% NA NA NA
Current
study
75 primary
21
recurrences
0% 31% 55% 48% 28 vs 50% Yes No
Abbreviations: FA¼ fibroadenoma; NA¼ not assessed; PT¼phyllodes tumour.
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borderline PTs at a frequency of 7%, but this requires further
validation in additional sample sets. In order to identify other
drivers of malignant PTs, further analysis of these unusual tumours
would be better carried out through exome or whole-genome
sequencing rather than targeted sequencing in order to detect
mutations in genes not currently known to be drivers of solid
cancers.
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